CY1117878T1 - Πυριδινo-2-αμιδια χρησιμα ως αγωνιστες του cb2 - Google Patents

Πυριδινo-2-αμιδια χρησιμα ως αγωνιστες του cb2

Info

Publication number
CY1117878T1
CY1117878T1 CY20161100762T CY161100762T CY1117878T1 CY 1117878 T1 CY1117878 T1 CY 1117878T1 CY 20161100762 T CY20161100762 T CY 20161100762T CY 161100762 T CY161100762 T CY 161100762T CY 1117878 T1 CY1117878 T1 CY 1117878T1
Authority
CY
Cyprus
Prior art keywords
pyridino
agents
amides useful
amides
useful
Prior art date
Application number
CY20161100762T
Other languages
English (en)
Inventor
Caterina Bissantz
Uwe Grether
Paul Hebeisen
Atsushi Kimbara
Qingping Liu
Matthias Nettekoven
Marco Prunotto
Stephan Roever
Mark Rogers-Evans
Tanja Schulz-Gasch
Christoph Ullmer
Zhiwei Wang
Wulun Yang
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of CY1117878T1 publication Critical patent/CY1117878T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)

Abstract

Η εφεύρεση σχετίζεται με μία ένωση του τύπου (I) όπου τα R1 έως R4 ορίζονται στην περιγραφή και στις αξιώσεις. Η ένωση του τύπου (I) μπορεί να χρησιμοποιηθεί ως φάρμακο.
CY20161100762T 2011-06-10 2016-08-03 Πυριδινo-2-αμιδια χρησιμα ως αγωνιστες του cb2 CY1117878T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2011075606 2011-06-10
PCT/EP2012/060785 WO2012168350A1 (en) 2011-06-10 2012-06-07 Pyridin- 2 -amides useful as cb2 agonists

Publications (1)

Publication Number Publication Date
CY1117878T1 true CY1117878T1 (el) 2017-05-17

Family

ID=46208600

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100762T CY1117878T1 (el) 2011-06-10 2016-08-03 Πυριδινo-2-αμιδια χρησιμα ως αγωνιστες του cb2

Country Status (36)

Country Link
US (2) US9321727B2 (el)
EP (2) EP2718266B9 (el)
JP (3) JP5997265B2 (el)
KR (1) KR20140042848A (el)
CN (2) CN103608332B (el)
AR (1) AR086881A1 (el)
AU (2) AU2012266369B2 (el)
BR (1) BR112013031463A2 (el)
CA (1) CA2835745A1 (el)
CL (1) CL2013003486A1 (el)
CO (1) CO6811864A2 (el)
CR (1) CR20130616A (el)
CY (1) CY1117878T1 (el)
DK (2) DK3072886T3 (el)
EA (2) EA023287B1 (el)
EC (1) ECSP13013074A (el)
ES (2) ES2588327T3 (el)
HK (1) HK1231465A1 (el)
HR (2) HRP20161064T2 (el)
HU (2) HUE027669T2 (el)
IL (2) IL229685B (el)
LT (1) LT3072886T (el)
MA (1) MA35245B1 (el)
MX (1) MX339992B (el)
MY (1) MY184978A (el)
PE (2) PE20141583A1 (el)
PH (1) PH12016501375A1 (el)
PL (2) PL3072886T3 (el)
PT (2) PT3072886T (el)
RS (2) RS57262B1 (el)
SG (1) SG10201604687QA (el)
SI (2) SI3072886T1 (el)
TR (1) TR201808273T4 (el)
TW (1) TWI567062B (el)
UA (1) UA114087C2 (el)
WO (1) WO2012168350A1 (el)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
BR112015009600A2 (pt) * 2012-12-07 2017-07-04 Hoffmann La Roche piridina-2-amidas úteis como agonistas cb2
SI2928882T1 (sl) 2012-12-07 2017-05-31 F. Hoffmann-La Roche Ag Pirazinski derivati kot agonisti receptorja CB2
JP6426618B2 (ja) * 2012-12-07 2018-11-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規なピリジン誘導体
WO2014086805A1 (en) * 2012-12-07 2014-06-12 F. Hoffmann-La Roche Ag Pyridine-2-amides useful as cb2 agonists
KR102369407B1 (ko) 2013-03-07 2022-03-02 에프. 호프만-라 로슈 아게 신규 피라졸 유도체
SI2978755T1 (en) * 2013-03-26 2018-03-30 F. Hoffmann-La Roche Ag New pyridine derivatives
HUE035333T2 (en) 2013-05-02 2018-05-02 Hoffmann La Roche Pyrrolo [2,3-d] pyrimidine derivatives as CB2 receptor agonists
PE20151977A1 (es) 2013-05-02 2016-01-07 Hoffmann La Roche Nuevos derivados de purina
CN106061480B (zh) * 2013-12-30 2020-02-28 莱福斯希医药公司 治疗性抑制性化合物
EA030032B1 (ru) * 2014-04-04 2018-06-29 Ф. Хоффманн-Ля Рош Аг 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
AR099933A1 (es) * 2014-04-04 2016-08-31 Hoffmann La Roche Derivados heterocíclicos de piridina agonistas de cb2
CN104004006B (zh) * 2014-05-15 2016-04-06 广州康瑞泰药业有限公司 一种3,6-二氢-2h-吡喃-4-硼酸频哪醇酯的合成方法
CN104003934B (zh) * 2014-06-13 2016-04-13 西华大学 6-氯-3-氟-2-吡啶甲酸的合成
GB201415569D0 (en) 2014-09-03 2014-10-15 C4X Discovery Ltd Therapeutic Compounds
EP4112611A3 (en) 2015-10-23 2023-03-22 Navitor Pharmaceuticals, Inc. Modulators of sestrin-gator2 interaction and uses thereof
EP3380455A1 (en) * 2015-11-26 2018-10-03 H. Hoffnabb-La Roche Ag Trypanosomes inhibitors
SI3386951T1 (sl) * 2015-12-09 2020-07-31 F. Hoffmann-La Roche Ag Fenilni derivati kot agonisti kanabinoidnega receptorja 2
GB201601703D0 (en) 2016-01-29 2016-03-16 C4X Discovery Ltd Therapeutic compounds
CA3026149A1 (en) 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
AR110770A1 (es) 2017-01-23 2019-05-02 Cadent Therapeutics Inc Moduladores del canal de potasio
US10912750B2 (en) 2017-04-26 2021-02-09 Navitor Pharmaceuticals, Inc. Modulators of Sestrin-GATOR2 interaction and uses thereof
CN110753690B (zh) 2017-06-20 2023-12-05 豪夫迈·罗氏有限公司 吡啶衍生物
EP3814337A1 (en) 2018-06-27 2021-05-05 F. Hoffmann-La Roche AG Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists
EP3814329B1 (en) * 2018-06-27 2024-01-17 F. Hoffmann-La Roche AG Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
EP3814328A1 (en) * 2018-06-27 2021-05-05 F. Hoffmann-La Roche AG Novel azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
US20200085810A1 (en) * 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders
CA3117336A1 (en) 2018-10-24 2020-04-30 Navitor Pharmaceuticals, Inc. Polymorphs of (s)-2-amino-5,5-difluoro-4,4-dimethylpentanoic acid for use in modulating mtorc1
CN109665982B (zh) * 2019-01-22 2022-07-08 深圳市第二人民医院 奈非西坦中间体2-吡咯烷酮的合成方法
BR112022008287A2 (pt) 2019-11-01 2022-07-26 Navitor Pharm Inc Métodos de tratamento usando um modulador de mtorc1
AU2021241530A1 (en) * 2020-03-23 2022-10-20 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
KR20230093251A (ko) 2020-09-10 2023-06-27 프리시릭스 엔.브이. Fap에 대한 항체 단편
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
WO2022272062A1 (en) * 2021-06-24 2022-12-29 Reservoir Neuroscience, Inc. Ep2 antagonist compounds
WO2023169984A1 (en) * 2022-03-11 2023-09-14 Syngenta Crop Protection Ag Herbicidal compounds
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9005965D0 (en) * 1990-03-16 1990-05-09 Shell Int Research Herbicidal carboxamide derivatives
GB9025828D0 (en) * 1990-11-28 1991-01-09 Shell Int Research Herbicidal carboxamide derivatives
AU643140B2 (en) * 1991-05-31 1993-11-04 Sumitomo Pharmaceuticals Company, Limited Leukotriene B4 antagonist
TW226012B (el) * 1991-11-19 1994-07-01 Dunlena Pty Ltd
GB2277930A (en) 1993-05-11 1994-11-16 Shell Int Research Herbicidal picolinamide derivatives
WO2003082191A2 (en) * 2002-03-28 2003-10-09 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
FR2838438A1 (fr) 2002-04-11 2003-10-17 Sanofi Synthelabo Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant
CN1703395A (zh) * 2002-08-09 2005-11-30 特兰斯泰克制药公司 芳基和杂芳基化合物以及调节凝血的方法
GB0222493D0 (en) 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
CN1933838A (zh) * 2004-02-12 2007-03-21 默克公司 作为代谢型谷氨酸受体－5调节剂的联吡啶酰胺
BRPI0513584A (pt) * 2004-07-21 2008-05-13 Mitsui Chemicals Inc derivado de diamina, processo de preparação deste e fungicida compreendendo derivado de diamina como um ingrediente ativo
EP1868999B1 (en) * 2005-04-06 2009-07-01 F. Hoffmann-Roche AG Pyridine-3-carboxamide derivatives as cb1 inverse agonists
EP2527337A1 (en) 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
WO2007011760A2 (en) * 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
EA015820B1 (ru) 2006-06-28 2011-12-30 Глэксо Груп Лимитед Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
AU2007300295A1 (en) * 2006-09-25 2008-04-03 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
EP2076499B1 (en) * 2006-10-04 2010-05-12 F.Hoffmann-La Roche Ag Pyrazine-2-carboxamide derivatives as cb2 receptor modulators
US8822497B2 (en) 2007-03-01 2014-09-02 Novartis Ag PIM kinase inhibitors and methods of their use
SE535157C2 (sv) * 2010-07-14 2012-05-02 Fairchild Semiconductor Konduktivitetsmodulering i en bipolär transistor i kiselkarbid
WO2012031817A1 (en) 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor

Also Published As

Publication number Publication date
SI3072886T1 (en) 2018-07-31
AU2012266369A1 (en) 2013-11-21
MX2013014564A (es) 2014-03-21
DK2718266T3 (en) 2016-06-13
AU2012266369B2 (en) 2016-11-10
HK1231465A1 (zh) 2017-12-22
HRP20180897T1 (hr) 2018-07-13
PL3072886T3 (pl) 2018-08-31
UA114087C2 (xx) 2017-04-25
JP6349360B2 (ja) 2018-06-27
HUE037666T2 (hu) 2018-09-28
CO6811864A2 (es) 2013-12-16
SI2718266T1 (sl) 2016-08-31
AU2017200801A1 (en) 2017-03-02
CR20130616A (es) 2018-01-26
ES2588327T9 (es) 2017-02-21
PT2718266T (pt) 2016-07-11
CN103608332B (zh) 2016-09-28
JP2017031162A (ja) 2017-02-09
CL2013003486A1 (es) 2014-11-03
DK3072886T3 (en) 2018-06-25
ECSP13013074A (es) 2014-01-31
EP2718266B9 (en) 2016-11-30
HUE027669T2 (en) 2016-11-28
EA023287B1 (ru) 2016-05-31
CN106349156A (zh) 2017-01-25
RS55073B1 (sr) 2016-12-30
EP3072886B1 (en) 2018-04-18
PT3072886T (pt) 2018-06-12
EA201391822A1 (ru) 2014-05-30
PH12016501375A1 (en) 2017-12-11
JP2018150367A (ja) 2018-09-27
PE20141583A1 (es) 2014-10-25
PE20180037A1 (es) 2018-01-09
EP3072886A1 (en) 2016-09-28
NZ715284A (en) 2017-06-30
AU2017200801B2 (en) 2018-11-22
NZ617464A (en) 2016-01-29
TWI567062B (zh) 2017-01-21
BR112013031463A2 (pt) 2016-12-06
WO2012168350A1 (en) 2012-12-13
US20160137606A1 (en) 2016-05-19
RS57262B1 (sr) 2018-08-31
CN103608332A (zh) 2014-02-26
PL2718266T3 (pl) 2016-11-30
TR201808273T4 (tr) 2018-07-23
CA2835745A1 (en) 2012-12-13
IL256826B (en) 2018-08-30
HRP20161064T2 (hr) 2017-02-24
EP2718266B1 (en) 2016-05-25
SG10201604687QA (en) 2016-07-28
MA35245B1 (fr) 2014-07-03
TW201311645A (zh) 2013-03-16
EA027247B1 (ru) 2017-07-31
ES2673614T3 (es) 2018-06-25
KR20140042848A (ko) 2014-04-07
EA201591527A1 (ru) 2016-04-29
ES2588327T3 (es) 2016-11-02
CN106349156B (zh) 2018-12-11
LT3072886T (lt) 2018-07-10
RS55073B9 (sr) 2019-07-31
MX339992B (es) 2016-06-21
IL229685B (en) 2018-02-28
JP5997265B2 (ja) 2016-09-28
US9321727B2 (en) 2016-04-26
US20120316147A1 (en) 2012-12-13
JP2014516071A (ja) 2014-07-07
IL229685A0 (en) 2014-01-30
MY184978A (en) 2021-04-30
EP2718266A1 (en) 2014-04-16
HRP20161064T1 (hr) 2016-10-21
JP6484746B2 (ja) 2019-03-13
AR086881A1 (es) 2014-01-29

Similar Documents

Publication Publication Date Title
CY1117878T1 (el) Πυριδινo-2-αμιδια χρησιμα ως αγωνιστες του cb2
CY1118950T1 (el) Νεα παραγωγα πυραζολιου
CY1118593T1 (el) Πρωτοτυπα παραγωγα πυραζινης
UA114656C2 (uk) Похідні піридину
MY179412A (en) Pyridine-2-amides useful as cb2 agonists
UA114655C2 (uk) Піридин-2-аміди, придатні як агоністи канабіноїдного рецептора 2
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
UY34523A (es) Derivados de betulina
UY34365A (es) Compuestos heterociclicos
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
CR20140079A (es) Aminoquinazolinas como inhibidores de quinasa
CY1116984T1 (el) ΠΑΡΑΓΩΓΑ [1,2,3]ΤΡΙΑΖΟΛΟ[4,5-d]ΠΥΡΙΜΙΔΙΝΗΣ ΩΣ ΑΓΩΝΙΣΤΕΣ ΥΠΟΔΟΧΕΑ ΚΑΝΝΑΒΙΝΟΕΙΔΩΝ 2
CY1119114T1 (el) ΠΑΡΑΓΩΓΑ ΠΥΡΡΟΛΟ[2,3-b] ΠΥΡΙΜΙΔΙΝΗΣ ΩΣ ΑΓΩΝΙΣΤΕΣ ΥΠΟΔΟΧΕΑ CB2
UA116239C2 (uk) Нові похідні піридину
UY34442A (es) 2-tiopirimidinonas.
UA109804C2 (xx) 2-метоксипіридин-4-ільні похідні
MX2014008918A (es) Nuevos derivados de pirrolidina.
UY33905A (es) Inhibidores de la catepsina c
TR201110248A2 (tr) 3,7-Bis(2-hydroxyethyl) icaritin bileşeninin gribal enfeksiyon tedavisinde kullanımı.
TN2011000162A1 (fr) نظام هندسي ومعماري مبتكر لانشاء البناء عامة ومواكب للتكنولوجيات المتطورة مادته الاساسية الطين والتربة
TN2011000372A1 (fr) جهاز مراقبة وتحكم في استهلاك المياه